The Potential Role of Ribonuclease P 25kDa Subunit in Cancer and Neurodegenerative Diseases

Target Name: RPP25

NCBI ID: G54913

RPP25

The Potential Role of Ribonuclease P 25kDa Subunit in Cancer and Neurodegenerative Diseases

Ribonuclease P 25kDa subunit (RPP25) is a protein that is expressed in various cell types of the human body, including bacteria, archaea, and eukaryotes. It is a member of the P25 subfamily of the nucleases, which are a group of enzymes that are involved in the DNA repair process. RPP25 is characterized by its unique subunit structure, consisting of a 25 kDa subunit that is composed of 115 amino acids.

The functional role of RPP25 in various cell processes is still being well understood, but it is known to play a significant role in DNA repair and gene regulation. RPP25 is involved in the repair of DNA double-strand breaks, as well as in the regulation of gene expression.

Due to its unique subunit structure and its involvement in various cellular processes, RPP25 has been identified as a potential drug target or biomarker. Several studies have suggested that RPP25 may be a promising drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the reasons for the interest in RPP25 as a potential drug target is its ability to interact with a variety of different drug targets. RPP25 has been shown to interact with several different protein targets, including those involved in cell signaling pathways, DNA repair pathways, and cell adhesion. This suggests that RPP25 may be a good candidate for drugs that target these pathways.

In addition to its potential as a drug target, RPP25 has also been identified as a potential biomarker for a variety of diseases. The Ribonuclease P 25kDa subunit is highly expressed in many different types of cancer, and it has been shown to be involved in the regulation of cancer cell growth and survival. Additionally, RPP25 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another potential application of RPP25 as a biomarker is its ability to be used as a diagnostic tool. The Ribonuclease P 25kDa subunit is expressed in many different types of cells in the human body, and it has been shown to be involved in the regulation of cellular processes. This suggests that RPP25 may be a useful biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, Ribonuclease P 25kDa subunit (RPP25) is a protein that is expressed in various cell types of the human body, and it is involved in a variety of cellular processes. Its unique subunit structure and its involvement in DNA repair and gene regulation make it a promising candidate for drug targeting, as well as a potential biomarker for a variety of diseases. Further research is needed to fully understand the functional role of RPP25 in various cell processes and to determine its potential as a drug target or biomarker.

Protein Name: Ribonuclease P And MRP Subunit P25

Functions: Component of ribonuclease P, a ribonucleoprotein complex that generates mature tRNA molecules by cleaving their 5'-ends (PubMed:12003489, PubMed:16723659, PubMed:30454648). Also a component of the MRP ribonuclease complex, which cleaves pre-rRNA sequences (PubMed:28115465)

The "RPP25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPP25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets